Phio Pharmaceuticals Corp. (PHIO) Stock Analysis

What Phio Pharmaceuticals Corp. does

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.

Key metrics

ETFs linked to PHIO

Broad-market and Healthcare sector ETFs an investor holding Phio Pharmaceuticals Corp. is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PHIO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Phio Pharmaceuticals Corp.?

Phio Pharmaceuticals Corp. trades under the ticker PHIO on NASDAQ.

Which exchange is PHIO listed on?

PHIO is listed on NASDAQ.

What sector does Phio Pharmaceuticals Corp. operate in?

Phio Pharmaceuticals Corp. is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PHIO in a portfolio?

PortView shows PHIO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.